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Abstract
The BH3 domain of Bcl-2 proteins was regarded as indispensable for apoptosis induction and for mutual regulation of family
members. We recently described Bcl-xAK, a proapoptotic splice product of the bcl-x gene, which lacks BH3 but encloses BH2,
BH4 and a transmembrane domain. It remained however unclear, how Bcl-xAK may trigger apoptosis. For efficient
overexpression, Bcl-xAK was subcloned in an adenoviral vector under Tet-OFF control. The construct resulted in significant
apoptosis induction in melanoma and nonmelanoma cell lines with up to 50% apoptotic cells as well as decreased cell
proliferation and survival. Disruption of mitochondrial membrane potential, and cytochrome c release clearly indicated
activation of the mitochondrial apoptosis pathways. Both Bax and Bak were activated as shown by clustering and
conformation analysis. Mitochondrial translocation of Bcl-xAK appeared as an essential and initial step. Bcl-xAK was critically
dependent on either Bax or Bak, and apoptosis was abrogated in Bax/Bak double knockout conditions as well by
overexpression of Bcl-2 or Bcl-xL. A direct interaction with Bcl-2, Bax, Bad, Noxa or Puma was however not seen by
immunoprecipitation. Thus besides BH3-mediated interactions, there exists an additional way for mutual regulation of Bcl-2
proteins, which is independent of the BH3. This pathway appears to play a supplementary role also for other proapoptotic
family members, and its unraveling may help to overcome therapy resistance in cancer.
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Introduction
Apoptosis is a defined genetic death program that leads to
ordered destruction of cellular components while membrane
integrity is preserved [1]. It also represents a safeguard mechanism
against tumor formation, due to the elimination of altered and
mutated cells. Thus, apoptosis resistance is characteristic for tumor
cells, and therapeutic strategies aim to overcome this resistance
[2].
Two major apoptosis pathways (extrinsic and intrinsic) have
been described in detail. Extrinsic pathways are initiated by
binding of death ligands (TNF-a, CD95L and TRAIL) to cell
surface receptors, leading to the formation of death-inducing
signaling complexes, where initiator caspases 8 and 10 are
activated [3,4]. On the other hand, intrinsic/mitochondrial
apoptosis pathways are triggered by intracellular signals such as
by cellular or DNA damage. Key events are depolarization of the
mitochondrial membrane potential (Dym) and mitochondrial
outer membrane permeabilisation (MOMP) resulting in cyto-
chrome c release and subsequent activation of initiator caspase 9
[5]. Initiator caspases cleave and activate downstream effector
caspases, which target a large number of death substrates to set
apoptosis into work [6,7].
Mitochondrial activation is critically controlled by the family of
pro- and antiapoptotic Bcl-2 proteins [8]. These proteins share
homology in four conserved regions termed Bcl-2 homology
domains (BH) and in a transmembrane domain (TM). Anti-
apoptotic proteins as Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and Bfl-1/A1
enclose all four BH domains whereas proapoptotic Bcl-2
homologues subdivide in the Bax/Bak group characterized by
BH 1–3, and the BH3-only group enclosing several proteins i.e.
Bad, Bid, Bik/Nbk, Bim, Noxa and Puma. In present models, Bax
and Bak drive MOMP and are neutralized by antiapoptotic family
members. The BH3-only proteins contribute to the regulation
either as sensitizers through inhibition of antiapoptotic Bcl-2
proteins or as direct activators of Bax and Bak [8,9].
Mutual regulation and neutralization has been described as
based on the formation of heterodimers between Bcl-2 family
members. Thus, the BH3 domain of proapoptotic Bcl-2 proteins
encloses an amphipathic a helix, which binds to a hydrophobic
groove formed by BH1, BH2 and BH3 of antiapoptotic members
[10]. In a rheostat model, the balance of pro- and antiapoptotic
Bcl-2 proteins determines the fate of a cell [11]. In melanoma,
apoptosis deficiency has been attributed to high expression of
antiapoptotic Bcl-2 proteins [12,13].
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family members. Thus, the bcl-x gene is expressed as a long
antiapoptotic form (Bcl-xL) and a short proapoptotic form (Bcl-xS)
[14]. We have recently described Bcl-xAK (atypical killer), a new
proapoptotic splice product which encloses BH2, BH4 and TM. It
completely lacks the BH3 domain, which has been regarded so far
as indispensable for the proapoptotic function [15].
For unraveling the mechanism of Bcl-xAK-mediated apoptosis
and exploring its possible therapeutic potential, we constructed an
adenoviral vector, which mediates its efficient and conditional
expression. We show that Bcl-xAK clearly activated the mitochon-
drial pathway, and its activity was critically controlled by both pro-
and anti-apoptotic Bcl-2 proteins, despite the lack of BH3. Thus, a
new model is suggested, in which Bcl-xAK acts as an atypical killer
to trigger Bax/Bak-dependent apoptosis.
Materials and Methods
Cell culture and cell lines
Three representative human melanoma cell lines, SK-Mel-13
[16], Mel-2a and A-375 [17] were investigated. For analyzing the
function of Bax and Bak, the prostate carcinoma cell line DU145
(DSMZ, Braunschweig, Germany) and the colon carcinoma cell
line HCT116 (ATCC, Maryland, MD, USA) were used.
Parental DU145 cells are deficient for Bax and reveal only
moderate expression of Bak. The cells had been reconstituted by
EGFP-tagged Bax or Bak, resulting in DU145-EGFP-Bax and
DU145-EGFP-Bak, as described previously [18]. HCT116
parental cells express both Bax and Bak. Isogenic sublines with
either Bax knockout or Bak knockdown as well as Bax
2/Bak
2
double knockdown cells had been kindly provided by B. Vogelstein
(John Hopkins Cancer Center, Baltimore) [18]. Subclones of A-
375 melanoma cells resulted from stable tansfection of a pIRES-
Bcl-2 plasmid (A375-Bcl-2) or the pIRES empty plasmid (A375-
Mock), as previously described [13]. The pIRES plasmid
originated from Clontech (Palo Alto, California, USA).
Cell lines were cultured at 37uC, 5% CO2 in DMEM (Gibco,
Karlsruhe, Germany) supplemented with 10% FCS and antibiotics
(Biochrom, Berlin, Germany). For caspase inhibition, cells were
preincubated for 1 h with 10 mM of the pancaspase inhibitior
zVAD-fmk (R&D Systems, Wiesbaden, Germany), which binds
the active sites of caspase-like proteases.
Construction of Bcl-xAK adenovirus
Bcl-xAK full-length cDNA [15] was subcloned into the Ad5
adenoviral vector pAd5-tTA, according to a strategy described
previously [19]. In brief, the cDNA was inserted into the TRE-
containing pHVAd2 shuttle vector. The resulting TRE-Bcl-xAK
expression cassette was then inserted into pAd5-tTA by homol-
ogous recombination, thereby replacing the E1 region and
creating pAdV-AK DNA (Fig. 1A). This was transfected into
HEK293 cells, and adenoviral plaques corresponding to AdV-AK
were propagated. Expression of Bcl-xAK after AdV-AK transduc-
tion was suppressed by addition of 1 mg/ml doxycycline to the
culture medium (OFF condition), whereas omitting doxycycline
resulted in promoter induction (ON condition). An adenoviral
vector for expression of myc-tagged Bik/Nbk (Ad5-myc-Nkb-
tTA=AdV-Nbk), used here as control, had been described
previously [19]. A luciferase-encoding adenovirus (Ad5-CMV-
Luc) served as mock control for adenovirus transduction and was
applied at the same MOI [20].
Apoptosis, cytotoxicity, cell proliferation and viability
For quantification of apoptosis, cell cycle analyses were carried
out, and apoptotic cells corresponded to cell populations with
hypodiploid nuclei [21]. Therefore, cells were seeded in 24-well
plates (50,000 cells per well). After incubation, cells were harvested
by trypsinisation, washed with ice-cold phosphate-buffered saline
(PBS) and incubated for 1 h with the staining buffer, containing
0.1% sodium citrate, 0.1% triton X-100 and propidiumiodide (PI;
40 mg/ml; Sigma-Aldrich, Taufkirchen, Germany). The DNA
content of nuclei was determined by using flow cytometry
(FACSCalibur and CellQuest software; Becton Dickinson, Heidel-
berg, Germany). As a second assay for quantification of apoptosis,
a cell death detection ELISA (Roche Diagnostics, Mannheim,
Germany) was applied, which detects mono and oligonucleosomes
formed in apoptotic cells. Cytotoxicity was determined in parallel
by a cytotoxicity detection assay (Roche Diagnostics), which
measures LDH activity in culture fluids. As positive controls for
induced cytotoxicity, cells were completely lysed by triton X-100
or were treated with doxorubicin (500 nM, 72 h). Protocols for
apoptosis ELISA and LDH release were according to the
manufacturer with minor modifications [22].
Cell proliferation (as a product of cell number and mitochon-
drial activity) was quantified according to the cleavage of the
water-soluble tetrazolium salt WST by mitochondrial dehydroge-
nases in viable cells (WST-1 assay, Roche Diagnostics). Cells were
seeded in a density of 10,000 per 100 ml in 96-well plates, and
treatments started after 24 h. At the time of analysis, WST-1
reagent was added and absorbance (450 nm) was determined in an
ELISA reader. Data were reported in percent of non-treated
controls. Cell viability at the single cell level was monitored by the
life-cell labeling dye calcein-AM. Briefly, 10
5 cells were incubated
with calcein (4 mM; eBioscience, Frankfurt, Germany) in serum-
free growth medium (60 min, 37uC). After PBS washing, cell
viability was determined by flow cytometry, comparing calcein-
stained (viable) and unstained (dead) cells.
For identification of chromatin condensation and nuclear
fragmentation in course of apoptosis, cells were harvested by
trypsinisation, centrifuged on cytospins and fixed for 30 min in 4%
formaldehyde. Cytospins were stained with bisbenzimide
(Hoechst-33258; Sigma, Taufkirchen, Germany; 1 mg/ml,
30 min) and examined by fluorescence microscopy. Apoptotic
cells were identified by fragmented nuclei or by bright blue-stained
nuclei with condensed chromatin. For quantitative evaluation,
fields with 100–200 cells were assessed in triplicates.
Cell transfection
Melanoma cells were seeded in six-well plates with 2610
5 cells/
well. For transient transfection, cells at a confluence of 50% were
washed with serum-free Opti-MEM medium (Life Technologies,
Carlsbad, CA, USA), followed by incubation at 37uC in Opti-
MEM for 4 h with plasmid DNA (2.5 or 5 mg/ml) and 0.1%
DMRIE-C (Life Technologies). Detailed protocols for transient
cell transfection had been described previously [22]. Plasmid
constructs of pcDNA3 (Invitrogen, Eugene, OR, USA) were used
for transient transfection to express full length Bcl-xL and Bcl-xAK.
Mitochondrial membrane potential and ROS
For determination of the mitochondrial membrane potential
(Dym), the fluorescent dye JC-1 (5,59,6,69-tetrachloro-1,19,3,39-
tetraethyl-benzimidazolyl carbocyanine iodide) or the dye
TMRM
+ (Tetramethyl rhodamine methyl ester perchlorate) were
used (both from Sigma-Aldrich). Cells were harvested by
trypsinisation and stained for 15 min at 37uC with JC-1
Regulation of Bcl-2 Proteins Independent of BH3
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e34549Regulation of Bcl-2 Proteins Independent of BH3
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34549(2.5 mM) or TMRM
+ (1 mM), and changes of Dym were
determined by flow cytometry.
For measurement of intracellular ROS levels, the fluorescent
dye H2DCFDA (29,7 9- dichloro-dihydro-fluorescein-diacetate)
was used. Cells were stained for 30 min with 15 mM H2DCFDA
(Molecular Probes, Invitrogen), harvested by trypsinisation,
resuspended in HBSS buffer (Biochrom, Berlin, Germany) and
analyzed by flow cytometry. For ROS scavenging, N-acetyl
cysteine (NAC, Sigma-Aldrich) was used in a concentration of
200 mM.
Assays for Bax/Bak activation
For determination of Bax and Bak clusters indicative for Bax/
Bak activation, DU145 cells were used, which had been stably
transfected for expression of EGFP-Bax or EGFP-Bak, respectively
[18]. Cells were seeded, transduced with AdV-AK (MOI=50) and
were cultured for 48 h with or without doxycycline. Bax and Bak
clustering was demonstrated by a fluorescence microscope
(Olympus BX50, Hamburg, Germany). For semi-quantitative
evaluation, at least 500 cells of each condition were assessed.
For analysis of Bax/Bak conformational changes related to
activation, primary antibodies specific for Bax/Bak N-terminal
domains were applied in flow cytometry (Bax-NT, Upstate, Lake
Placid, USA, #06-499; Bak-NT, Merck, Darmstadt, Germany,
#AM04). Melanoma cells (10
5) were harvested by trypsinisation
and fixed for 30 min with 4% paraformaldehyde in PBS. Cells
were suspended in saponin buffer (1% FCS, 0.1% saponin in PBS)
and incubated for 1 h at 4uC in the dark with antibodies Bax-NT
(1:100) or Bak-NT (1:10). As secondary antibodies, goat anti-rabbit
IgG (H+L)-FITC (Jackson Immuno Research, West Grove, USA)
and goat anti-mouse IgG (H+L)-FITC (SouthernBiotech, Birming-
ham, AL, USA) were used. After washing and resuspension, cells
were immediately measured by flow cytometry.
Western blot analysis
Detailed protocols for protein extraction and Western blot
analysis had been described previously [22]. As a standard, 10
6
cells were harvested and dissolved in lysis buffer (150 mM NaCl,
1 mM EDTA, 0.5% SDS, 0.5% Nonidet P-40, 2 mM PMSF,
1 mM leupeptin, 1 mM pepstatin, 10 mM Tris-HCl, pH 7.5). For
analysis of cytochrome c and mitochondrial localization of Bcl-2
proteins, cytosolic and mitochondrial cell fractions were separated
by a mitochondria/cytosol fractionation kit (Alexis, Gru ¨nberg,
Germany).
The following primary antibodies were used: procaspase-3 (Cell
Signaling, Danvers, MA, USA; rabbit; 1:1000), cleaved caspase-3
(Cell Signaling; rabbit; 1:1000), caspase-8 (Cell Signaling; mouse;
1:1000), caspase-9 (Cell Signaling; rabbit; 1:1000), Bcl-xL (Santa
Cruz, Heidelberg, Germany; mouse; 1:200), mouse Bcl-2 (Santa
Cruz; mouse; 1:200), human Bcl-2 (Santa Cruz; mouse; 1:200),
Mcl-1 (Santa Cruz; rabbit; 1:200), Bax (Santa Cruz; rabbit; 1:200),
Bak (Assay Biotechnology, Sunnyvale, CA, USA; rabbit; 1:500),
Bad (Cell Signaling; rabbit; 1:1000), Puma (Epitomics, Burlin-
game, CA USA; rabbit; 1:1000), Noxa (ProSci Incorporated,
Poway, CA, USA; rabbit; 1:500), cytochrome c (BD Biosciences,
Heidelberg, Germany; mouse; 1:1000), c-Myc (Calbiochem,
Nottingham, UK; mouse; 1:500), anti-porin 31 HL (VDAC;
Calbiochem; mouse; 1:5000), Glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH; Santa Cruz; mouse; 1:1000), b-actin (Sigma-
Aldrich; mouse; 1:5000). As secondary antibodies, peroxidase-
labeled goat anti-rabbit and goat anti-mouse antibodies were used
(Dako, Hamburg, Germany; 1:5000).
Immunoprecipitation with anti-Myc microbeads
Melanoma cells (10
6, SK-Mel-13) were transiently transfected
with plasmids encoding myc-tagged Bcl-2 proteins (0.1% DMRIE-
C, 5 mg/ml plasmid). After 24 h (for Bcl-xL and Bax) or 48 h (for
Bcl-xAK), cells were harvested, washed with ice-cold PBS and
resuspended in 1 ml of pre-cooled lysis buffer (150 mM NaCl, 1%
triton X-100, 50 mM Tris-HCl, pH 8). Microbeads covered with
monoclonal anti-myc antibodies were given to the lysate for
magnetic labelling of the tagged proteins. Beads and bound
proteins were captured on flow-through magnetic columns,
washed 46 with buffer 1 (150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 8) and
washed for another time with 20 mM Tris-HCl (pH 7.5). Proteins
were eluted with hot (95uC) elution buffer (50 mM DTT, 1%
SDS, 1 mM EDTA, 0.005% bromphenol blue, 10% glycerol,
50 mM Tris-HCl, pH 6.8). No secondary antibodies were needed.
The mock control were melanoma cells transiently transfected
with an empty pcDNA3 plasmid. The mock control proved that
the anti-Myc beads do not result in any non-specific precipitates.
Immunoprecipitation of myc-tagged proteins was carried out with
the mMACS c-myc-tagged protein isolation kit (Miltenyi Biotec,
Bergisch-Gladbach, Germany). Lysates and immunoprecipitates
were investigated by Western blot analysis.
Results
Delayed but efficient apoptosis induction
For investigating the efficacy and mechanism of Bcl-xAK-
mediated apoptosis, an adenoviral vector was constructed with the
Figure 1. Efficient induction of cell death by Bcl-xAK. (A) The structure of the adenoviral construct AdV-AK is shown. The adenoviral E1 region
was replaced by the Bcl-xAK cDNA driven by a tetracyclin-responsive promoter (PTRE), and the E3 region was replaced by the tetracyclin-controlled
transactivator (tTA) driven by a CMV promoter (PCMV). The tTA mediates Tet-OFF regulation. Striped boxes indicate the poly(A)+ regions. (B) Bcl-xAK
expression as determined by Western blot analysis is shown in melanoma cell lines SK-Mel-13, A-375 and Mel-2a at 48 h after transduction with AdV-
AK (MOI=50). Cells had received doxycycline (OFF condition) or were left without (ON condition). Equal protein loading was confirmed by b-actin. (C)
Left, examples of cell cycle analysis after PI staining indicating sub-G1 apoptotic cell populations in Mel-2a at 48 h of transduction. Middle panel,
detached and rounded cells indicating apoptosis are shown of Mel-2a at 48 h after transduction with AdV-AK under OFF and ON conditions. Right
panel, chromatin condensation and nuclear fragmentation were visualized by bisbenzimide (DAPI) staining in Mel-2a at 48 h after AdV-AK
transduction (MOI=50). D–F) Time course analyses of apoptosis (D, flow cytometry after PI staining), cytotoxicity (E, LDH release) and cell proliferation
(F, WST-1 assay) are shown for SK-Mel-13, A-375 and Mel-2a cells at 24, 48 and 72 h after transduction with AdV-AK (50 MOI, +Dox=Off, 2Dox=On).
As positive controls for induced cytotoxicity, cell lines were completely lysed by triton X-100 (T=100%) or were treated with doxorubicin (D, 500 nM,
72 h). WST-1 values are expressed as percent of non-treated controls (=100%). (G) For comparison, apoptosis induction (sub-G1 cells) by AdV-Nbk is
shown for Mel-2a cells at 24 h, 48 h and 72 h (MOI=50). AdV-Nbk shares the same backbone with AdV-AK. For induction, doxycycline was omitted
(On). (H) A time course analysis of Bcl-xAK expression (3–48 h) after AdV-AK transduction and promoter induction is shown for Mel-2a, as determined
by Western blot analysis. (I) Cell survival was determined according to calcein staining in Mel-2a cells at 48 h of Bcl-xAK induction. A shift to the left
indicates calcein-negative (=non viable) cells. (J) Quantification of the calcein experiment. (D, E, F, G, J) Means and standard deviations of triplicate
values of representative experiments are shown. A luciferase-encoding adenovirus (Ad5-CMV-Luc) applied at the same MOI served as mock control
(M), for controlling adenovirus transduction. All experiments were performed at least twice, resulting in highly comparable results.
doi:10.1371/journal.pone.0034549.g001
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inserted into the adenoviral E1 region. The tetracycline/
doxycycline repressible transactivator tTA was located in the
adenoviral E3 region (Fig. 1A). The construct mediated high
expression of Bcl-xAK in melanoma cell lines as shown for SK-
Mel-13, A-375 and Mel-2a, when doxycycline was omitted (ON
condition), whereas addition of doxycycline almost completely
abolished Bcl-xAK expression (OFF condition, Fig. 1B).
Significant induction of apoptosis, as determined by counting
hypodiploide sub-G1 cells, was seen in melanoma cell lines after
transduction and promoter activation, whereas doxycyline strongly
diminished apoptosis (Fig. 1D, examples shown in 1C left panel).
Kinetic analyses revealed a delayed induction of apoptosis in the
three cell lines, which increased to 12%–23% at 48 h and to 17%–
37% at 72 h after transduction (Fig. 1D). In contrast, other
proapoptotic Bcl-2 proteins induced apoptosis already at 24 h, as
shown here for the BH3-only protein Bik/Nbk subcloned in the
same adenoviral background (Fig. 1G). The delay in apoptosis
induction by Bcl-xAK occurred despite its adenovirus-mediated
high expression already at 6 h after transduction (Fig. 1H).
Comparable results concerning increased DNA fragmentation
were obtained by an apoptosis ELISA (data not shown).
In parallel with DNA fragmentation, clearly visible effects
indicating apoptosis were evident, as reduced cell numbers,
rounded and detached cells (Fig. 1C, middle panel). Chromatin
condensation and nuclear fragmentation, typical hallmarks in
apoptosis, were seen after bisbenzimide staining (Fig. 1C, right
panel). At 48 h after transduction of Bcl-xAK, the cell numbers
with atypical nuclei increased from 4% (Off) to 33% (On).
LDH release monitoring loss of plasma membrane integrity was
determined to exclude early necrotic cell death. Indeed, LDH
release was not significant at 48 h, when apoptosis was already
induced, and it was less affected at 72 h, as compared to
cytotoxicity controls (Fig. 1E). As determined by WST-1 assay,
Figure 2. Activation of caspases and mitochondria. (A) Processing of caspase-3, -8 and -9 is shown in Mel-2a cells at 24 h and at 48 h after
transduction with AdV-AK (MOI=50). Expression of Bcl-xAK was switched on in the absence of doxycycline (ON) or shut off with doxycycline (OFF).
Equal protein loading (20 mg/lane) was confirmed by GAPDH. The whole experiment was performed twice. (B) Inhibition of apoptosis by
preincubation with the pancaspase inhibitor zVAD-fmk (1 h, 10 mM) is shown. SK-Mel-13 cells had been transduced with AdV-AK (MOI=100, 48 h).
Means and SDs of triplicate values of a representative experiment (one of two) are shown. (C) Decrease of the mitochondrial membrane potential
(Dym) is shown for Mel-2a cells at 48 h after transduction of AdV-AK, as determined by flow cytometry after JC-1 or TMRM
+ staining. Cultures with
doxycycline (OFF, grey) are compared to cultures grown in the absence of doxycycline (ON, open graphs). The experiment was performed three
times, resulting in highly comparable results. (D) ROS levels were determined in Mel-2a cells at 24 h and 48 h after transduction with AdV-AK under
ON and OFF conditions (flow cytometry after H2DCFDA staining). Below, parallel cultures were pre-treated for 1 h with 200 mM NAC before
transduction. (E) Relative DNA-fragmentation rates (apoptosis) at 48 h with or without NAC were determined in parallel. Non-transduced cells (2/
+NAC) are shown as additional controls (open bars). Values had been normalized with regard to non-treated controls, set to 1. Means and SDs of
triplicate values of a representative experiment are shown (two independent experiments). (F) Expression levels of Bcl-2 proteins, of p53 and Survivin
were determined by Western blot analysis in Mel-2a cells at 24 h and 48 h after transduction with AdV-AK (ON and OFF conditions). Equal protein
loading (20 mg/lane) was confirmed by GAPDH.
doi:10.1371/journal.pone.0034549.g002
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loss of 60% at 72 h (Fig. 1F). Also cell viability, determined by calcein
staining, was decreased (38% in Mel-2a at 72 h), as compared to 6%
under Off conditions (Fig. 2I, J). Thus, Bcl-xAK triggered delayed but
efficient induction of apoptosis in melanoma cells.
Activation of caspases and mitochondria through
adenovirus-encoded Bcl-xAK
Targeting of the caspase cascade was investigated in Mel-2a
cells by Western blot analyses for the initiator caspases 8 and 9 as
well as for the main effector caspase 3. Under conditions of high
adenovirus-mediated expression of Bcl-xAK and strong apoptosis
induction, also significant processing of these caspases was evident
at 48 h of transduction (Fig. 2A). Underlining the role of caspases,
Bcl-xAK-induced apoptosis was almost completely blocked by the
pancaspase inhibitor zVAD-fmk (10 mM; Fig. 2B).
The effects on mitochondrial proapoptotic pathways were
monitored by two distinct mitochondrial membrane potential
(Dym)-dependent dyes. Both JC-1 and TMRM
+ revealed the same
result, namely decrease of Dym upon Bcl-xAK expression.
Interestingly, loss of Dym appeared already at 24 h after AdV-
AK transduction, thus proving this as an early step in Bcl-xAK
signal transduction, before apoptosis became evident (Fig. 2C).
Reactive oxidative species (ROS) are regarded as an additional
step in apoptosis regulation. Increased ROS levels were deter-
mined by flow cytometry after H2DCFDA staining and found in
Mel-2a cells at 48 h but not at 24 h after transduction, thus
characterizing this step likely as a consequence of apoptosis
(Fig. 2D). Thus, increased ROS may further enhance the
apoptotic effect, which was proven by pretreatment for 1 h with
the antioxidant N-acetyl cysteine (NAC). Neutralization of ROS
by NAC (Fig. 3D) resulted in a two-fold decrease of Bcl-xAK-
induced apoptosis (Fig. 2E).
Despite the clear involvement of the mitochondrial pathway,
levels of other Bcl-2 proteins remained rather stable after
transduction with AdV-AK, as shown by Western blot analysis
at 24 h and at 48 h for Bcl-2, Mcl-1, Bax, Puma and Noxa.
Similarly, there were no significant changes of the levels of p53 or
Survivin (Fig. 2F).
Dependency on Bax and Bak
To address the relation of Bcl-xAK-induced cell death to Bax
and Bak, we used a HCT116-derived colon carcinoma cell model.
This consisted of parental Bax
+/Bak
+ cells and sublines with either
Bax knockout or Bak knockdown as well as Bax
2/Bak
2 double
knockdown cells (Fig. 3A). AdV-AK (50 MOI, 48 h) revealed
strong apoptosis induction in parental cells, whereas both Bax and
Bak single knockdown significantly diminished apoptosis, indicat-
ing that both proteins may be engaged by Bcl-xAK. In accordance,
Bcl-xAK-induced apoptosis was completely abrogated in the
double knockdown cells (Fig. 3B).
Figure 3. Bcl-xAK-mediated apoptosis depends on Bax or Bak. (A, C) Expression of Bax and Bak is shown by Western blot analysis in subclones
of HCT116 and DU145, respectively. Equal loading was confirmed by incubation with b-actin. Two independent series of protein extracts revealed
largely comparable expression. (B) HCT116 parental cells (Bax
+/Bak
+) as well as subclones (Bax
2/Bak
+), (Bax
+/Bak
2) and (Bax
2/Bak
2) were transduced
with AdV-AK (MOI=50) and cultured under OFF or ON conditions. Relative DNA fragmentation values (apoptosis ELISA) were normalized according
to the values of parental cells under OFF conditions (set to 1). (D) DU145 parental cells (Bax
2/EGFP-Bak
2) as well as subclones (Bax
2/EGFP-Bak
+) and
(EGFP-Bax
+/EGFP-Bak
2) were transduced with AdV-AK (MOI=50, 100) and cultured under OFF or ON conditions. The percentages of apoptotic cells
(sub-G1 populations) are shown, as determined by flow cytometry at 48 h after transduction. (B, D) Means and SDs of triplicate values of a
representative experiment are shown (each two independent experiments). Statistical significance as determined by Student’s t-test is indicated by
asterisks (*, p,0.05; **, p,0.005), when comparing parental cells and subclones under ON conditions.
doi:10.1371/journal.pone.0034549.g003
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cell model was applied. Parental cells are deficient for Bax and
reveal only moderate activity of Bak. They had been reconstituted
for either Bax or Bak expression by using EGFP-tagged copies
(Fig. 3C). Parental DU145 cells were clearly non-responsive to
AdV-AK, possibly indicating an endogeneous non-functional Bak.
However, the reconstitution of either Bax or Bak strongly
enhanced Bcl-xAK-mediated apoptosis, resulting in each case in
more than 50% apoptotic cells. This again showed that Bcl-xAK
can induce apoptosis via both Bax and Bak (Fig. 3D).
Formation of Bax/Bak clusters has been reported as related to
proapoptotic function [23]. For monitoring this step, DU145 cells
were used that had been stably transfected with EGFP-Bax and
EGFP-Bak, respectively. In agreement with the function of both Bax
and Bak, Bcl-xAK expression resulted in visible clustering of both
EGFP-Bax and EGFP-Bak at 48 h after transduction. Clustering
induced by Bcl-xAK w a sc o m p a r a b l et ot h ee f f e c t so fd o x o r u b i c i n
(2 mM, 24 h), used as positive control (Fig. 4A). Evaluations revealed
Bax/Bak clusters in 20%–30% of cells, similar to apoptosis
inductions at these conditions (Fig. 4B). In course of Bax/Bak
activation, conformational changes may lead to exposure of their N-
termini. Flow cytometry with N-terminus-specific antibodies (Bax-
NT, Bak-NT) showed activation of Bax and Bak in 30% of Mel-2a
cells in response to Bcl-xAK expression (Fig. 4C, 4D).
Abrogation of Bcl-xAK-mediated apoptosis by
antiapoptotic Bcl-2 proteins
To address the role of antiapoptotic Bcl-2 proteins, A-375
melanoma cells stably transfected for Bcl-2 overexpression (A375-
Bcl-2) were applied. These cells were completely protected against
the proapoptotic effects of Bcl-xAK, whereas mock-transfected cells
(A375-Mock) revealed about 30% apoptotic cells at 48 h of
transduction with AdV-AK (Fig. 5A). A similar result was obtained
after Bcl-xL overexpression. Transient transfection of a Bcl-xAK
expression plasmid significantly enhanced apoptosis in SK-Mel-13
melanoma cells at 48 h, whereas the co-transfection of a Bcl-xL
expression plasmid almost completely prevented Bcl-xAK-induced
apoptosis (Fig. 5B). Thus, either one or these antiapoptotic
proteins was sufficient to block Bcl-xAK-mediated apoptosis. Loss
of Dym was also seen in A375-Mock, which was completely
prevented by Bcl-2 overexpression in A375-Bcl-2 (Fig. 5C).
Mitochondrial translocation of Bcl-xAK is not prevented
by Bcl-2
Hallmarks in mitochondrial apoptosis pathways are transloca-
tion of Bax and release of mitochondrial factors. Significant
cytochrome c release was seen in Mel-2a and in A375-Mock at
48 h after AdV-AK transduction (Fig. 6A). Also higher levels of
Figure 4. Bax and Bak activation after Bcl-xAK overexpression. (A) For investigation of Bax and Bak clustering, DU145 cells stably transfected
for expression of EGFP-Bax or EGFP-Bak were transduced with AdV-AK and cultured for 48 h under OFF or ON conditions. Doxorubicin-treated cells
(2 mM, 24 h) were used as positive controls. Examples of fluorescence microscope images taken at 48 h after transduction and promoter induction
are shown. (B) A quantitative evaluation of Bax and Bak clustering was performed (means and SDs of triplicate values of a representative experiment).
A second experiment revealed comparable results. (C) Bax and Bak activation upon Bcl-xAK expression was determined in Mel-2a at 48 after AdV-AK
transduction (50 MOI), by flow cytometry after staining with conformation-specific antibodies against Bax and Bak N termini (Bax/Bak NT). The bars
indicate the populations counted as positive for activated Bax and Bak, respectively. (D) A quantification of triplicate values (one experiment of two
independent) is shown. Transduction with AdV-Nbk (50 MOI) is shown for comparison.
doi:10.1371/journal.pone.0034549.g004
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Bax translocation and activation is underestimated as some
cytosolic contaminations (up to 5%) were still left in mitochondrial
fractions seen by the cytosolic marker GAPDH. This may explain
the weaker bands of Bax already before induction of Bcl-xAK
expression (Fig. 6B).
The localization of Bcl-xAK itself appeared as an important step.
When comparing 24 h with 48 h, the amount of Bcl-xAK in the
cytosol significantly decreased at 48 h by 2–3-fold in all three cell
lines. Equal loading of cytosolic extracts was proven by b-actin
(Fig. 6A). The direct comparison of the mitochondrial extracts at
24 h and 48 h clearlyshowed almost noBcl-xAK inMel-2a and only
weak bands in the two A-375 clones at 24 h. The mitochondrial
localization of Bcl-xAK however strongly increased at 48 h (Fig. 6B).
Simultaneous decrease of Bcl-xAK in the cytosol and its strong
increase in mitochondria at 48 h clearly proved mitochondrial
translocation of Bcl-xAK, which is suggestive as a critical step for
inductionofapoptosis.Importantly,themitochondrialtranslocation
of Bcl-xAK was not prevented by Bcl-2, whereas cytochrome c
release and Bax translocation were completely blocked (Fig. 6A; B).
No interaction of Bcl-xAK with other Bcl-2 family members
For investigating whether Bcl-xAK might directly interact with
other Bcl-2 proteins, SK-Mel-13 melanoma cells were transiently
transfected with myc-tagged copies of Bcl-xAK, Bcl-xL or Bax.
Following immunoprecipitation with anti-Myc microbeads, bind-
ing of Bcl-2, Bax, Bad, Noxa and Puma was investigated by
Western blotting. Mock transfected cells were used as controls and
ruled out non-specific precipitations by the microbeads. On the
other hand, Myc-tagged proteins were efficiently immunoprecip-
itated, as seen in the pellet (P) fractions after incubation with the
Myc antibody (Fig. 7A, panels 1–3).
The binding analyses revealed characteristic interactions, thus
proving the reliability of the assay. Thus binding of Bcl-2 to myc-
Bax, binding of Bax to myc-Bcl-xL and myc-Bax as well as binding
of Bad to myc-Bcl-xL were seen (Fig. 7A). Apoptosis, monitored in
parallel, was induced by myc-Bax and myc-Bcl-xAK, whereas myc-
Bcl-xL diminished basal apoptotic rates, thus providing a proof on
the function of the transfected proteins (data not shown). However,
no direct interactions of the five representatives of the Bcl-2 family
were seen with Bcl-xAK (Fig. 7A), thus suggesting that Bcl-xAK
displays its activation of Bax and Bak in an indirect way via a not
yet defined step. In this pathway Bcl-xAK and antiapoptotic family
members act independent of each other on Bax and Bak (Fig. 7B).
Discussion
Pro- and antiapoptotic Bcl-2 proteins are critically involved in
apoptosis regulation by controlling mitochondrial cell death
Figure 5. Bcl-2 and Bcl-xL block the proapoptotic effects of Bcl-xAK. (A) Subclones of A-375 cells stably transfected with pIRES-Bcl-2 (A375-
Bcl-2) or mock-transfected (A375-Mock) were transduced with AdV-AK under OFF or ON conditions. Non-transduced cells (2) were used as additional
controls. Numbers of apoptotic cells (sub-G1 cell populations) were determined by flow cytometry after PI staining. (B) SK-Mel-13 melanoma cells
were transiently transfected with either Bcl-xL or Bcl-xAK alone or with a combination of both (each 2.5 mg plasmid-DNA). Relative DNA fragmentation
values, as determined at 24 h and 48 h after transfection, were calculated with respect to cells that had received only the transfection lipid (white
bars). (A, B) Means and SDs of triplicate values of a representative experiment are shown (each two independent experiments). Overexpression of Bcl-
2, Bcl-xL and Bcl-xAK, as determined by Western blot analyses, is shown in the insets. (C) The mitochondrial membrane potential (Dym) was
determined by flow cytometry after TMRM staining in A375-Mock and in A375-Bcl-2 at 24 h and 48 h. After transduction with AdV-AK, inducible and
non inducible conditions were compared (On/Off). The experiment was performed three times, giving comparable results.
doi:10.1371/journal.pone.0034549.g005
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differential splicing, leading to an enhanced complexity. Thus, up
to 10 splice products have been reported for the bim gene, of which
BimS, BimL and BimEL have been characterized. Also eight splice
products with different domain structures have been reported for
the bax gene, of which Bax-a is best characterized [24,25].
Another example is given by the bcl-x gene, which is expressed in
four reported isoforms with different activities. Besides Bcl-xL
(long), antiapoptotic functions have also been reported for Bcl-xES
(extra short) [26,27]. In contrast, Bcl-xS (short) and Bcl-xAK
(atypical killer) exert proapoptotic functions [14,15]. Alternative
splicing is a target of specific regulations. Thus, the switch from
Bcl-xL to Bcl-xS in response to genotoxic stress was related to an
ATM/CHK2/p53-dependent pathway [28]. The pathway, which
triggers Bcl-xAK expression, is not yet defined.
Bcl-2 proteins are categorized in three subfamilies according to
different domain structures, enclosing antiapoptotic proteins (BH
1–4), the Bax/Bak group (BH 1–3) and BH3-only proteins [9].
The bcl-x splice products, however, reveal unique structures. Thus,
Bcl-xS encloses BH3 and BH4 [24], whereas Bcl-xAK encloses
BH2 and BH4 [15]. Despite the BH3 domain has been regarded
as indispensible for proapoptotic functions [12], we had previously
categorized Bcl-xAK as proapoptotic based on a moderate
induction of apoptosis in melanoma cells (two-fold), after plasmid
transfection [15]. For unraveling Bcl-xAK-mediated pathways, we
have constructed an adenoviral vector, which drives its high and
conditional expression under Tet-OFF control. With this efficient
expression system, Bcl-xAK induced apoptosis in up to 40% of
melanoma and in 50% of non-melanoma cells. In its efficacy, Bcl-
xAK was comparable to the BH3-only protein Bik/Nbk, which was
available in the same adenoviral backbone [19].
Under AdV-AK-mediated high expression of Bcl-xAK, signifi-
cant caspase activation became evident, in contrast to previous
findings under moderate expression of Bcl-xAK [15]. Thus, caspase
activation by Bcl-xAK in melanoma cells appeared as dependent
on its expression level. Initiator caspases of both extrinsic and
intrinsic pathways (caspase-8, and 29) were cleaved. However,
caspase-8 may also be activated downstream of caspase-3 in a
described amplification loop [29], which is suggestive for Bcl-xAK.
Bcl-2 family proteins are particularly involved in the control of
mitochondrial apoptosis pathways, which can be induced by
overexpression of BH3-only proteins as well as by overexpression
of Bax or Bak [18,30,31]. Also, Bcl-xAK resulted in significant
decrease of mitochondrial membrane potential and in cytochrome
c release, thus clearly indicating parallels to other proapoptotic
Bcl-2 proteins. Although Bax/Bak-independent mechanisms were
also discussed [32], mitochondrial activation is mainly related to
Bax or Bak function [9]. Here again, Bcl-xAK revealed typical
characteristics of proapoptotic Bcl-2 proteins, namely a strong
dependency on either Bax or Bak. Both proteins share a similar
structure and related functions [33]. Some proapoptotic Bcl-2
proteins show preference for activating either Bax or Bak, as Bik/
Figure 6. Bcl-2 blocks Bcl-xAK-mediated cytochrome c release and Bax translocation. Mel-2a, A375-Mock and A375-Bcl-2 cells were
transduced with AdV-AK (MOI=50) and were kept under OFF and ON conditions. At 24 h and 48 h, cytosolic fractions (Cyto) and mitochondrial
fractions (Mito) were isolated and analysed by Western blotting. Non-transfected controls (2) are shown as controls. The whole experiment was
performed two times, resulting in highly comparable results. (A) Cytosolic extracts were analyzed for showing expression of Bcl-xAK and release of
cytochrome c. Mitochondrial extracts serve as positive controls, the mitochondrial protein VDAC ruled out any contaminations of cytosolic extracts
with mitochondria, and b-actin served as loading control. (B) Mitochondrial extracts were analyzed for showing mitochondrial translocation of Bcl-2
proteins. Here, cytosolic extracts served as controls, equal protein loading was confirmed by VDAC and the relative purity of mitochondrial extracts
was examined by GAPDH. 5% of the total mitochondrial fractions and 2% of the total cytosolic fractions had been loaded on the gels.
doi:10.1371/journal.pone.0034549.g006
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Bcl-xAK, however, Bak expression could compensate for loss of
Bax and vice versa, and apoptosis induction was abolished only in
Bax/Bak double deficient cells. This suggests that Bcl-xAK may
may drive more general changes at the mitochondrial membrane
rather than selectively targeting a specific protein.
Importantly, after transduction all melanoma cells were
responsive to Bcl-xAK, as the whole cell population showed
reduced Dym, increased ROS as well as activated Bax and Bak.
However, certain thresholds may prevent full apoptosis induction
in the majority of cells. This may be related to the activity of
antiapoptotic Bcl-2 family members, which may block Bax and
Bak. Thus, overexpression of Bcl-2 abrogated apoptosis induced in
melanoma cells by Bik/Nbk [35,36], and Bcl-xL inhibited Bax-
induced apoptosis in mouse embryonic fibroblasts [37]. These
antiapoptotic activities had been described as dependent on BH3-
mediated heterodimerization. However, also the proapoptotic
effects of Bcl-xAK were completely inhibited by Bcl-2 or Bcl-xL.
This may depend on the inhibition of Bax and Bak by the
antiapoptotic proteins, rather than on direct inhibition of Bcl-xAK.
In agreement, Bcl-2 could not prevent Bcl-xAK mitochondrial
translocation.
Highly characteristic for Bcl-xAK-induced apoptosis was a time
delay of 48 h, whereas other Bcl-2 proteins as Bik/Nbk and Bcl-xS
induced apoptosis in melanoma cells already at 24 h [35,36]. In
general, proapoptotic signaling as mutual regulation of Bcl-2
proteins, cytochrome c release and caspase activation are rather
quick cellular events [38]. The time delay of Bcl-xAK in contrast to
other proapoptotic Bcl-2 proteins is indicative for an indirect
mechanism enclosing a time-consuming step. No relation was seen
to the expression of other Bcl-2 proteins. Rather, Bcl-xAK
mitochondrial localization appeared as a critical step, and
membrane transport may play a regulatory role therein. Whereas
Bcl-xAK was cytosolic at 24 h, it translocated to mitochondria at
48 h, when apoptosis was induced. Also other proapoptotic Bcl-2
proteins have to translocate to mitochondria to exert their
proapoptotic activities, as shown for tBid and Bax [5,39]. Thus,
apoptosis by Bcl-xAK appeared as tightly linked to its presence in
mitochondria, where it resulted in Bax and Bak activation.
An interesting finding was that loss of Dym preceded
translocation of Bcl-xAK and MOMP. The relation between
Dym and MOMP is still a matter of discussion; one effect may
precede the other or they may even occur independently of each
other [40,41]. Loss of Dym may result from uncoupling of the
mitochondrial electron transport chain which may lead to Bax and
Bak oligomerization [42]. Mitochondrial dynamics appears as
another important level, which may be influenced by Bcl-xAK
overexpression. Mitochondrial dynamics may contribute to the
control of MOMP, which is further dependent on Bax [43].
Formation of large Bax/Bak clusters has been suggested, which
may translocate to mitochondrial constriction sites, to drive
MOMP [23]. Clustering of Bax and Bak was clearly induced in
response to Bcl-xAK, thus further relations to mitochondrial fission
and fusion may be expected.
For BH3-only proteins, different mechanisms have been
suggested to explain their proapoptotic activities. In the neutral-
ization/displacement model, BH3-only proteins bind antiapopto-
tic family members, to release Bax or Bak [5]. This activity is
based on BH3, which binds to the hydrophobic groove of
antiapoptotic Bcl-2 proteins [44]. According to a second model,
BH3-only proteins may also directly bind and activate Bax or Bak,
which has been shown for tBid, Bim and Puma [38,45,46]. This
activity is also regarded as BH3-dependent. Thus, direct, although
week binding of Bim to Bax has been shown, which was abrogated
by the replacement of the Bim BH3 [30]. Also peptides of the BH3
domains of Bid, Bim and Puma were able to drive direct activation
of Bax [45]. Both ways of apoptosis induction can not apply to Bcl-
xAK, due to its lack of BH3.
A third way of apoptosis induction has been recently suggested.
It is explained by a general remodelling of the mitochondrial outer
Figure 7. Co-immunoprecipitation analyses of Bcl-xAK with Bcl-2 family members. (A) SK-Mel-13 melanoma cells were transiently
transfected with each 5 mg of pcDNA3 plasmids encoding Bcl-xL, Bcl-xAK, Bax or empty vector (Mock). Cells lysates were immunoprecipitated with
microbeads covered with anti-Myc antibody, and immunoprecipitates were analysed by Western blotting. Non-bound supernatants (S) were
compared with the immunoprecipitated pellet fractions (P). Antibodies for immunodetection: anti- Myc, Bcl-2, Bax and Bad. The complete experiment
was performed two times, which both gave the same result. (B) A model for apoptosis induction by Bcl-xAK is suggested. It is based on mitochondrial
translocation of Bcl-xAK and activation of Bax/Bak. Bcl-2/Bcl-xL prevent Bax/Bak activation but not Bcl-xAK translocation. BH3-only proteins may
mediate a BH3 domain-dependent pathway via inactivation of antiapoptotic Bcl-2 proteins and may also drive a BH3-independent pathway
analogous to Bcl-xAK (see discussion part).
doi:10.1371/journal.pone.0034549.g007
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proteins, which resulted in Bax activation [47]. Of note, this
proapoptotic activity appeared as independent of the BH3
domain. Thus for the BH3-only protein Bnip3, the transmem-
brane domain (TM) has been proven as essential for its
proapoptotic activity, whereas BH3 could be mutated without
major effect on apoptosis induction [48]. Also for BimS, deletion or
point mutation of its BH3 on one hand prevented the interaction
with Bcl-2 and Bax but remained largely without effect on
apoptosis induction. BimS mutants still localized to mitochondria,
suggesting that this was the critical step, and indeed, when the TM
was deleted, the proapoptotic activity was lost [49]. Also for Bcl-
xAK, mitochondrial translocation appeared as the critical step. A
deletion analysis for Bcl-xAK may become particularly helpful for
identification of proapoptotic domain(s) independent of BH3, as
overlapping functions with BH3 are here excluded.
Thus, the characterization of Bcl-xAK strongly supports
speculations on proapoptotic pathways that are mediated by Bcl-
2 proteins but act independent of the BH3 domain. These
pathways are nevertheless critically dependent on Bax and Bak as
well as on antiapoptotic Bcl-2 family members. As shown here for
melanoma, colon and prostate carcinoma cells, activation of these
pathways can be effective in cancer cells. Bcl-2 proteins are of
critical importance for therapy resistance in cancer, as particularly
seen in melanoma [2]. Thus, new pathways for regulating Bcl-2
protein activity are of particular interest and may become useful
for targeting so far therapy-refractory tumors, such as melanoma.
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